Guangzhou LBP Medicine Science & Technology Co Ltd (688393) - Net Assets
Based on the latest financial reports, Guangzhou LBP Medicine Science & Technology Co Ltd (688393) has net assets worth CN¥1.20 Billion CNY (≈ $175.41 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.31 Billion ≈ $191.99 Million USD) and total liabilities (CN¥113.31 Million ≈ $16.58 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Guangzhou LBP Medicine Science & Technol liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.20 Billion |
| % of Total Assets | 91.36% |
| Annual Growth Rate | 28.33% |
| 5-Year Change | 5.5% |
| 10-Year Change | 472.9% |
| Growth Volatility | 80.65 |
Guangzhou LBP Medicine Science & Technology Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Guangzhou LBP Medicine Science & Technology Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 688393 total assets for the complete picture of this company's asset base.
Annual Net Assets for Guangzhou LBP Medicine Science & Technology Co Ltd (2011–2024)
The table below shows the annual net assets of Guangzhou LBP Medicine Science & Technology Co Ltd from 2011 to 2024. For live valuation and market cap data, see 688393 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.23 Billion ≈ $180.24 Million |
-0.53% |
| 2023-12-31 | CN¥1.24 Billion ≈ $181.20 Million |
+1.31% |
| 2022-12-31 | CN¥1.22 Billion ≈ $178.87 Million |
+1.04% |
| 2021-12-31 | CN¥1.21 Billion ≈ $177.02 Million |
+3.61% |
| 2020-12-31 | CN¥1.17 Billion ≈ $170.85 Million |
+162.60% |
| 2019-12-31 | CN¥444.63 Million ≈ $65.06 Million |
+14.21% |
| 2018-12-31 | CN¥389.32 Million ≈ $56.97 Million |
+12.43% |
| 2017-12-31 | CN¥346.28 Million ≈ $50.67 Million |
+7.90% |
| 2016-12-31 | CN¥320.94 Million ≈ $46.96 Million |
+49.27% |
| 2013-12-31 | CN¥215.00 Million ≈ $31.46 Million |
+24.05% |
| 2012-12-31 | CN¥173.32 Million ≈ $25.36 Million |
+260.43% |
| 2011-12-31 | CN¥48.09 Million ≈ $7.04 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Guangzhou LBP Medicine Science & Technology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1137.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥381.37 Million | 30.37% |
| Common Stock | CN¥93.57 Million | 7.45% |
| Other Comprehensive Income | CN¥59.81 Million | 4.76% |
| Other Components | CN¥720.99 Million | 57.42% |
| Total Equity | CN¥1.26 Billion | 100.00% |
Guangzhou LBP Medicine Science & Technology Co Ltd Competitors by Market Cap
The table below lists competitors of Guangzhou LBP Medicine Science & Technology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HCK Capital Group Bhd
KLSE:7105
|
$336.41 Million |
|
Settlebank Corporation
KQ:234340
|
$336.48 Million |
|
Eche Izquierdo
SN:EISA
|
$336.55 Million |
|
Neurogene Inc
NASDAQ:NGNE
|
$336.56 Million |
|
Echomarketing Co.Ltd
KQ:230360
|
$336.12 Million |
|
IVF Hartmann Holding AG
SW:VBSN
|
$336.00 Million |
|
Motech Industries Co Ltd
TWO:6244
|
$335.94 Million |
|
ABC arbitrage SA
PA:ABCA
|
$335.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangzhou LBP Medicine Science & Technology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,263,611,314 to 1,255,740,454, a change of -7,870,860 (-0.6%).
- Net income of 21,291,313 contributed positively to equity growth.
- Dividend payments of 14,507,228 reduced retained earnings.
- Other comprehensive income increased equity by 59,811,980.
- Other factors decreased equity by 74,466,925.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥21.29 Million | +1.7% |
| Dividends Paid | CN¥14.51 Million | -1.16% |
| Other Comprehensive Income | CN¥59.81 Million | +4.76% |
| Other Changes | CN¥-74.47 Million | -5.93% |
| Total Change | CN¥- | -0.62% |
Book Value vs Market Value Analysis
This analysis compares Guangzhou LBP Medicine Science & Technology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.83x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 35.40x to 1.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.69 | CN¥24.55 | x |
| 2012-12-31 | CN¥2.50 | CN¥24.55 | x |
| 2013-12-31 | CN¥3.03 | CN¥24.55 | x |
| 2016-12-31 | CN¥4.52 | CN¥24.55 | x |
| 2017-12-31 | CN¥4.89 | CN¥24.55 | x |
| 2018-12-31 | CN¥5.54 | CN¥24.55 | x |
| 2019-12-31 | CN¥6.35 | CN¥24.55 | x |
| 2020-12-31 | CN¥12.51 | CN¥24.55 | x |
| 2021-12-31 | CN¥12.90 | CN¥24.55 | x |
| 2022-12-31 | CN¥12.95 | CN¥24.55 | x |
| 2023-12-31 | CN¥13.25 | CN¥24.55 | x |
| 2024-12-31 | CN¥13.42 | CN¥24.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangzhou LBP Medicine Science & Technology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.52%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.09x
- Recent ROE (1.70%) is below the historical average (14.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 56.46% | 30.95% | 0.79x | 2.32x | CN¥22.34 Million |
| 2012 | 16.00% | 25.81% | 0.56x | 1.11x | CN¥10.40 Million |
| 2013 | 18.15% | 26.95% | 0.55x | 1.21x | CN¥17.26 Million |
| 2016 | 14.59% | 19.09% | 0.68x | 1.13x | CN¥14.48 Million |
| 2017 | 14.10% | 18.56% | 0.63x | 1.20x | CN¥14.06 Million |
| 2018 | 15.89% | 20.07% | 0.64x | 1.23x | CN¥22.79 Million |
| 2019 | 16.69% | 20.83% | 0.66x | 1.21x | CN¥29.66 Million |
| 2020 | 7.26% | 22.57% | 0.29x | 1.11x | CN¥-32.05 Million |
| 2021 | 6.63% | 18.17% | 0.32x | 1.13x | CN¥-40.62 Million |
| 2022 | 2.39% | 5.78% | 0.36x | 1.13x | CN¥-93.53 Million |
| 2023 | 3.17% | 8.06% | 0.36x | 1.11x | CN¥-86.30 Million |
| 2024 | 1.70% | 4.52% | 0.35x | 1.09x | CN¥-104.28 Million |
Industry Comparison
This section compares Guangzhou LBP Medicine Science & Technology Co Ltd's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,585,373,438
- Average return on equity (ROE) among peers: 5.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangzhou LBP Medicine Science & Technology Co Ltd (688393) | CN¥1.20 Billion | 56.46% | 0.09x | $336.14 Million |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $1.79 Billion | 0.80% | 1.04x | $521.28 Million |
| Blue Sail Medical Co Ltd (002382) | $203.26 Million | 29.44% | 0.87x | $1.08 Billion |
| Andon Health Co Ltd (002432) | $1.54 Billion | 0.94% | 0.53x | $4.93 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $3.13 Billion | 12.99% | 0.84x | $1.34 Billion |
| Guangzhou Improve Med Instrument (300030) | $563.53 Million | 4.77% | 0.17x | $380.05 Million |
| QITIAN Technology Group Co Ltd (300061) | $1.16 Billion | -31.55% | 0.49x | $950.81 Million |
| Shanghai Tofflon Science Tech (300171) | $3.12 Billion | 2.26% | 0.50x | $1.47 Billion |
| Truking Technology Ltd (300358) | $2.32 Billion | 6.92% | 0.71x | $1.03 Billion |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $1.33 Billion | 15.49% | 0.52x | $782.31 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $694.06 Million | 12.68% | 0.39x | $2.51 Billion |
About Guangzhou LBP Medicine Science & Technology Co Ltd
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China and internationally. The company offers pathological diagnostic reagents and ancillary equipment that consists of liquid-based cytology products, including liquid-based cytology production machines and automatic sample transfer machines; polymerase… Read more